Literature DB >> 15019645

Histidine-tryptophan-ketoglutarate solution maximally preserves endothelium-derived hyperpolarizing factor-mediated function during heart preservation: comparison with University of Wisconsin solution.

Qin Yang1, Rong-Zhen Zhang, Anthony P C Yim, Guo-Wei He.   

Abstract

BACKGROUND: The University of Wisconsin (UW) solution is used widely in heart preservation but has been demonstrated to be detrimental to the endothelial function. The present study compares the effect of histidine-tryptophan-ketoglutarate (HTK) and UW solutions on endothelium-derived hyperpolarizing factor (EDHF)-mediated function in porcine small coronary arteries.
METHODS: An isometric force study was performed in a myograph and the membrane potential of a single smooth muscle cell was measured electrophysiologically. Small coronary arteries (diameter 457 +/- 15 microm) were incubated with UW (n = 8), HTK (n = 7) or Krebs solution (n = 15) at 4 degrees C for 4 hours. After washout, in the presence of indomethacin (Indo; 7 micromol/liter), N(G)-nitro-l-arginine (l-NNA; 300 micromol/liter) and oxyhemoglobin (HbO; 20 micromol/liter), bradykinin (BK; -10 to -6.5 log M)-induced relaxation was compared in U46619 (-8 log M) pre-contraction. EDHF-mediated hyperpolarization was elicited by BK (-6.5 log M) in the presence of Indo, l-NNA and HbO.
RESULTS: BK-induced, EDHF-mediated relaxation was reduced from 93.6 +/- 2.8% to 79.7 +/- 4.6% after UW preservation (p = 0.01 by unpaired t-test and p = 0.005 by 2-way analysis of variance [ANOVA]), whereas HTK incubation did not decrease EDHF-mediated relaxation (87.0 +/- 6.5%, p = 0.3 by unpaired t-test and p = 0.6 by 2-way ANOVA, compared with control, and p = 0.001 by 2-way ANOVA, compared with UW). EDHF-mediated hyperpolarization (10.3 +/- 1.6 mV) was attenuated by UW exposure (3.4 +/- 0.6 mV, [p = 0.002] vs control), but not by HTK exposure (8.3 +/- 1.1 mV, [p = 0.3] vs control).
CONCLUSIONS: HTK is superior to UW solution in protecting EDHF-mediated endothelial function in porcine small coronary arteries. The present findings supports the use of HTK solution in heart preservation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019645     DOI: 10.1016/S1053-2498(03)00187-6

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  Myocardial protection during minimally invasive mitral valve surgery: strategies and cardioplegic solutions.

Authors:  Jens Garbade; Piroze Davierwala; Joerg Seeburger; Bettina Pfannmueller; Martin Misfeld; Michael A Borger; Friedrich-Wilhelm Mohr
Journal:  Ann Cardiothorac Surg       Date:  2013-11

2.  Clinical comparative analysis of histidine-tryptophan-ketoglutarate solution and St. Thomas crystalloid cardioplegia: A 12-year study from a single institution.

Authors:  Ying-Zhong Lin; Jing-Bin Huang; Xiang-Wei Li; Xian-Ming Tang; Wei-Jun Lu; Zhao-Ke Wen; Jian Liang; Dian-Yuan Li; Hao Wang
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

Review 3.  Delayed graft function in the kidney transplant.

Authors:  A Siedlecki; W Irish; D C Brennan
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

4.  Effect of fetal anaemia on myocardial ischaemia-reperfusion injury and coronary vasoreactivity in adult sheep.

Authors:  Q Yang; A R Hohimer; G D Giraud; D M Van Winkle; M J Underwood; G-W He; L E Davis
Journal:  Acta Physiol (Oxf)       Date:  2008-09-20       Impact factor: 6.311

Review 5.  Protection of coronary endothelial function during cardiac surgery: potential of targeting endothelial ion channels in cardioprotection.

Authors:  Qin Yang; Cheuk-Man Yu; Guo-Wei He; Malcolm John Underwood
Journal:  Biomed Res Int       Date:  2014-07-13       Impact factor: 3.411

6.  Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.

Authors:  X W Li; Y Z Lin; H Lin; J B Huang; X M Tang; X M Long; W J Lu; Z K Wen; J Liang; D Y Li; X F Zhao
Journal:  Braz J Med Biol Res       Date:  2016-05-13       Impact factor: 2.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.